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E-mail address: manuela.merli@uniroma1.itIn thismulticentre study, 193 cirrhotic patients with infections
other than SBP, were randomly assigned to receive albumin infu-
sion or no treatment in addition to antibiotics. The primary out-
comes were renal failure and mortality rates. The study failed to
show any beneﬁcial effect on these outcomes, although albumin
infusion delayed the onset of renal failure. However, in our opin-
ion, some bias could have inﬂuenced the results. First, the preva-
lence of ascites was signiﬁcantly higher in the patients
randomized to albumin and antibiotics than in the patients
assuming antibiotics alone (75.8 vs. 59.6%; p = 0.017). The
development of infection and the consequent increase in vasodi-
latation may have inﬂuenced the rate of renal failure and progno-
sis of the former group differently from the control group inwhich
the number of patients with ascites was lower. Second, the suc-
cess or failure of antibiotic therapies were not analyzed and, as
we know, the course of infections is a further important parame-
ter for the prognosis of cirrhotic patients [5,6]. Third, as also dis-
cussed by the authors, many violations occurred in the protocol
and 17 patients in the control group also received albumin for
large volume paracentesis during the ﬁrst week.
Thus, in our opinion, the results of the present study should
not discourage further investigations in cirrhotic patients with
infections also considering the wide range of potential beneﬁts
of albumin administration in this setting (antioxidant function,
immunomodulation, anti-inﬂammatory activity and transport of
many endogenous and exogenous substances), in addition to its
well-known effect as plasma expander [7]. Among these
additional properties, in particular, the effect of the albumin
infusion during the therapy with moderately/highly protein-
bound antibiotics should also be evaluated, considering the
relevant role of hypoalbuminemia on the pharmacokinetics of
these antibiotics [8].
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768Reply to ‘‘Albumin infusion in cirrhotic patients with
non-SBP infections: End of the story?’’To the Editor:
We greatly appreciate the comments by Lucidi et al. [1]. Firstly,
we acknowledge that, despite well-conducted randomization to
reduce the risk of selection bias at trial entry [2], the presence
of ascites was more frequently reported in the albumin (ALB)
group as compared with the control group (75.8 vs. 59.6;
p = 0.017). We have to remember that using an alpha risk of 5%,
the probability of there being no imbalance between groups for
any one baseline characteristic is 0.95. Assuming the characteris-
tics are independent, there is a non-negligible 1  (0.95)n proba-
bility of observing a signiﬁcant imbalance between groups when
comparing n baseline characteristics. For instance, in Table 1
showing the baseline characteristics of patients [2], there were
at least 10 independent variables meaning that the chance of at
least one statistically signiﬁcant imbalance was 0.40. In order
to improve the precision of the treatment effect estimate, and
to avoid any confounding, the two Cox multivariate analyses per-
formed to determine predictive variables associated with renal
failure and death at 3 months were adjusted for ascites, which
was no longer signiﬁcant.
Open access under CC BY-NC-ND license.Journal of Hepatology 2015 vol. 63 j 763–773
Secondly, Lucidi et al. are right in stressing that we omitted to
accurately classify infections into healthcare-associated, nosoco-
mial or community-acquired, to analyze the pathogenic organ-
isms identiﬁed and the antibiotic resistance pattern, and to
prospectively record the occurrence of a second infection [3]. All
of these data are of considerable importance for outcome in cir-
rhotic patients. Our multicenter trial mainly aimed to evaluate
the effectiveness of albumin in real-life practice, without any
restriction on antibiotic prescriptions. In our study, nosocomial
infections were not signiﬁcantly associated with renal failure
(p = 0.53 by univariate Coxmodel) or death at 3 months (p = 0.13).
Finally, Lucidi et al. also underline the protocol violations
which may have diluted the treatment effect. These violations
are common in interventional research [4,5] and to counteract
such limitations, we performed sensitivity analyses to assess
the robustness of our results regarding our primary endpoint,
namely 3 month renal-failure-free survival. We performed; (1)
a per-protocol analysis, in which the 15 patients who did not
receive albumin infusion in the ALB group were excluded from
the analysis; (2) an as-treated analysis, in which patients were
analyzed according to the treatment they actually received; and
(3) a best-case scenario favouring albumin administration by
considering that all seven control patients and none of the four
ALB group patients with missing data on serum creatinine devel-
oped renal failure [2]. All these sensitivity analyses showed that
the 3 month renal-failure-free survival was not signiﬁcantly dif-
ferent between the ALB and control groups.
Despite these overall negative results, we observed that the
proportion of patients with renal failure at one-month was lower
among septic patientswith ascites and in patientswith severe sep-
sis after albumin infusion, suggesting a beneﬁcial effect of albumin
in both these dramatic conditions. Clearly, our messagewas not to
scare practitioners prescribing albumin in the setting of liver cir-
rhosis, since this drug is largely used all over the world in a wide
variety of clinical settings [6], and recent advances in this ﬁeld
have proved that albumin exerts a protective effect bymodulating
inﬂammation, oxidative and cellular stress [7]. However, it is our
duty to recommend caution regarding high volumes of albumin
administered and rapid infusion rates, which may lead to ﬂuid
overload in some patients with unrecognized heart disease.
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Randomized study of danoprevir/ritonavir-based therapy for HCV
genotype 1 patients with prior partial or null responses
to peginterferon/ribavirin
To the Editors:
With great interest I read the article by Prof. Feld et al. [1],
which concluded that danoprevir/r, mericitabine plus
PegIFNa-2a/ribavirin produced high rates of sustained virological
response 24 weeks after the end of treatment in prior partial and
null responders.
It is well know that the body mass index is associated with the
rates of sustained virological response (a body mass index greater
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